Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 12, 2024Frontiers in OncologyOpen Access

Enfortumab vedotin–related cutaneous toxicity correlates with overall survival in patients with urothelial cancer: a retrospective experience

View Full Paper
Ask AI
Bookmark
Share

Authors

EVEvangelia VlachouBJBurles A. JohnsonDMDavid J. McConkey

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Vlachou et al. (2024) studied this question.

synapsesocial.com/papers/68e64f8fb6db6435875e06d0https://doi.org/10.3389/fonc.2024.1377842
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Treatment‐Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the <scp>UNITE</scp> Study2025 · 9 citations
  2. 2Enfortumab vedotin (EV) related cutaneous toxicity to predict metabolic response on fluorodeoxyglucose (FDG)-positron emission tomography (PET) scan in advanced urothelial carcinoma (aUC): A single-center experience.2026
  3. 3Enfortumab Vedotin−Induced Cutaneous Toxic Effects and Survival in Urothelial Carcinoma2026
  4. 4Cutaneous and Renal Toxicities of Enfortumab Vedotin for Advanced Urothelial Carcinoma: The UROKYU Study2024 · 7 citations
  5. 5Real-world use of enfortumab vedotin in metastatic urothelial carcinoma: efficacy, safety, and risk stratification2026 · 3 citations